The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000606381
Ethics application status
Help: Ethics application status
Approved
Date submitted
Help: Date submitted
9/03/2026
Date registered
Help: Date registered
15/05/2026
Date last updated
Help: Date last updated
2/07/2026
Date data sharing statement initially provided
Help: Data sharing statement date
15/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Feasibility of CoMpression to Prevent Oxaliplatin induced Peripheral Neuropathy Symptoms (COMPRES)
Scientific title
Non-randomised feasibility study of compressive therapy using surgical gloves and compression stockings in patients receiving oxaliplatin for gastrointestinal malignancies.
Additional trial identifiers [1] 316729 0
None
Universal Trial Number (UTN)
Trial acronym
COMPRES
Related trial records

Health condition
Health condition(s) studied:
cancer 341009 0
neuropathy 341010 0
Condition category
Condition code
Cancer 337157 337157 0 0
Any cancer
Neurological 337985 337985 0 0
Other neurological disorders

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
This study is testing whether wearing compression garments—surgical gloves and compression stockings—can help reduce nerve damage (neuropathy) in patients receiving oxaliplatin chemotherapy for gastrointestinal cancers. The aim is to determine if patients can safely tolerate the compression garments and if wearing the garments can help reduce nerve damage (neuropathy) in patients receiving oxaliplatin chemotherapy for gastrointestinal cancers.

The study is non-randomised, which means patients are not randomly assigned to groups. All participants will receive the compression therapy while having their oxaliplatin-based chemotherapy.

The goal is to see if this simple method can safely and effectively manage one of the common side effects of oxaliplatin- peripheral neuropathy.

Participants will wear compression gloves (two surgical gloves per hand) and lower-limb compression stockings beginning 30 minutes before, during, and for 30 minutes after each oxaliplatin infusion. Oxaliplatin is typically administered every 2–3 weeks, depending on the chemotherapy regimen. The compression intervention will be used for a minimum of 12 weeks of treatment (approximately four to six cycles), unless oxaliplatin is discontinued earlier. Follow-ups will occur 12 and 24 weeks after end of oxaliplatin treatment.
Intervention code [1] 333427 0
Treatment: Devices
Description of the comparator or control
Nil
Control group
Uncontrolled

Outcomes
Primary outcome [1] 344678 0
Feasibility of adherence to compression therapy Feasibility will be measured by the proportion (%) of participants who adhere to wearing study garments during each oxaliplatin treatment cycle. The trial will be deemed feasible when 80% of enrolled participants adhere to wearing compression garments during the trial. Adherence is defined as the proportion of oxaliplatin infusions the participant attended during their time on study, up to death or withdrawal of consent, in which participants were documented to have worn the assigned garments on all available extremities = 50% of the required infusion time. Participants who withdraw from the intervention, but not from the study, will be considered non-adherent.
Timepoint [1] 344678 0
All participants enrolled will be considered evaluable for the primary endpoint. Patients who discontinued oxaliplatin treatment or compression before the 12-week assessment will be considered failures for the primary outcome measure
Secondary outcome [1] 460758 0
Adverse events
Timepoint [1] 460758 0
Baseline, 12-weeks and 24-week post treatment
Secondary outcome [2] 460759 0
Chronic oxaliplatin toxicity
Timepoint [2] 460759 0
12-weeks and 24-weeks post treatment
Secondary outcome [3] 460760 0
Oxaliplatin-induced peripheral neuropathy
Timepoint [3] 460760 0
12-weeks and 24-weeks post treatment
Secondary outcome [4] 460761 0
Infusion time - neurotoxicity symptoms
Timepoint [4] 460761 0
12-weeks and 24-weeks post treatment
Secondary outcome [5] 460762 0
Infusion time - during treatment
Timepoint [5] 460762 0
During treatment
Secondary outcome [6] 460763 0
Functional Assessment of Cancer Therapy/Gynecologic Oncology Group - Neurotoxicity (FACT-GOG-NTX-13 Questionnaire)
Timepoint [6] 460763 0
12-weeks and 24-weeks post treatment
Secondary outcome [7] 460764 0
Participant comfort/satisfaction
Timepoint [7] 460764 0
12-weeks and 24-weeks post treatment

Eligibility
Key inclusion criteria
Patients who meet all of the following criteria are eligible for enrolment onto the study.
1. Male or female patients aged 18 years or older
2. Patients with gastrointestinal malignancies who are scheduled to receive oxaliplatin containing regimens, oxaliplatin 85mg/m2 every 2 weeks or 130 mg/m2 every 3 weeks, for at least 12 weeks
3. Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2
4. Willing and able to provide informed consent
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Patients who meet any of the following criteria are not eligible for enrolment onto the study.
1. Current grade 2 or higher peripheral neuropathy. Patients with high risk for OIPN based on previous (neurotoxic) chemotherapy or diabetes mellitus are eligible provided they have grade 0 or 1 peripheral neuropathy at the time of inclusion.
2. Symptomatic peripheral vascular disease or peripheral arterial ischemia precluding use of compression garments
3. Allergy to natural rubber, latex, or surgical gloves
4. Dermatopathy, wound, or musculoskeletal problems of the hands at enrolment that would prevent safe application of compression garments
5. Taking current medications that may mitigate CIPN, including duloxetine, gabapentin/pregabalin, ketamine and tricyclic antidepressants
6. Unable or unwilling to comply with protocol requirements.

Study design
Purpose of the study
Prevention
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
The primary feasibility outcomes will be summarised descriptively as frequency and percentage. Secondary outcomes will be described for continuous outcomes as either mean and standard deviation, or as median and inter-quartile range, depending on distribution, and for categorical outcomes as frequency and percentage.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
TAS
Recruitment hospital [1] 29248 0
Icon Cancer Centre Hobart - Hobart
Recruitment postcode(s) [1] 45558 0
7000 - Hobart

Funding & Sponsors
Funding source category [1] 321334 0
Charities/Societies/Foundations
Name [1] 321334 0
Icon Cancer Foundation
Country [1] 321334 0
Australia
Primary sponsor type
Commercial sector/Industry
Name
Icon Group
Address
Country
Australia
Secondary sponsor category [1] 324070 0
None
Name [1] 324070 0
Address [1] 324070 0
Country [1] 324070 0

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 319872 0
St Vincent's Hospital Melbourne Human Research Ethics Committee
Ethics committee address [1] 319872 0
Ethics committee country [1] 319872 0
Australia
Date submitted for ethics approval [1] 319872 0
27/11/2025
Approval date [1] 319872 0
05/03/2026
Ethics approval number [1] 319872 0
LRR 491/25

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 148670 0
A/Prof Louise Nott
Address 148670 0
Icon Cancer Centre Hobart, 2 Melville Street, Hobart TAS 7000
Country 148670 0
Australia
Phone 148670 0
+61 03 6240 2600
Fax 148670 0
Email 148670 0
Contact person for public queries
Name 148671 0
Amma Owusu
Address 148671 0
Icon group (research) Level 1/22 Cordelia St, South Brisbane QLD 4101
Country 148671 0
Australia
Phone 148671 0
+61 07 3737 4500
Fax 148671 0
Email 148671 0
Contact person for scientific queries
Name 148672 0
Amma Owusu
Address 148672 0
Icon group (research) Level 1/22 Cordelia St, South Brisbane QLD 4101
Country 148672 0
Australia
Phone 148672 0
+61 07 3737 4500
Fax 148672 0
Email 148672 0

Data sharing statement
Will the study consider sharing individual participant data?
No
No IPD sharing reason/comment: Individual study data will not be shared.



What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.